ArticleBiomolecules2026
Synthesis, Biological Evaluation and Structure-Activity Relationship of Juglone Derived Naphthoquinones as Potential Antipsoriatic Agents.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disease for which the development of structurally novel and accessible small-molecule candidates remains of considerable interest. In this study, a series of juglone-derived naphthoquinone analogs was synthesized to explore the influence of substitution pattern on anti-inflammatory activity and cytotoxicity. Their biological profiles were first evaluated in LPS-stimulated HaCaT cells by combining cytotoxicity assessment with nitric oxide (NO) screening. Most derivatives showed reduced cytotoxicity compared with juglone, and preliminary structure-activity relationship analysis indicated that retention of a free hydroxyl group at the C-2 position was generally favorable for both reduction in NO release and cellular safety, whereas C-3 alkyl substitution tended to weaken activity and increase cytotoxicity. Among the tested compounds, compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.